ABSTRACT
Neurodegenerative diseases (ND) affect distinct populations of neurons and manifest various clinical and pathological symptoms. A subset of ND prognoses has been linked to vascular risk factors. Consequently, the current study investigated retinal vascular abnormalities in a murine model of Lafora neurodegenerative disease (LD), a fatal and genetic form of progressive myoclonus epilepsy that affects children. Here, arterial rigidity was evaluated by measuring pulse wave velocity and vasculature deformations in the retina. Our findings in the LD mouse model indicate altered pulse wave velocity, retinal vascular thinning, and convoluted retinal arteries.
Subject(s)
Disease Models, Animal , Lafora Disease , Retinal Vessels , Animals , Lafora Disease/genetics , Lafora Disease/pathology , Lafora Disease/physiopathology , Mice , Retinal Vessels/pathology , Mice, Inbred C57BL , Male , Myoclonic Epilepsies, Progressive/genetics , Myoclonic Epilepsies, Progressive/physiopathology , Myoclonic Epilepsies, Progressive/pathologyABSTRACT
Lafora disease (LD; OMIM#274780) is a fatal rare neurodegenerative disorder characterized by generalized epileptic seizures and the presence of polyglucosan inclusions (PGs), called Lafora bodies (LBs), typically in the brain. LD is caused by mutations in two genes EPM2A or EPM2B, which encode respectively laforin, a glucan phosphatase, and malin, an E3-ubiquitin ligase. Much remains unknown about the molecular bases of LD and, unfortunately, appropriate treatment is still missing; therefore patients die within 10 years from the onset of the disease. Recently, we have identified neuroinflammation as one of the initial determinants in LD. In this work, we have investigated anti-inflammatory treatments as potential therapies in LD. With this aim, we have performed a preclinical study in an Epm2b-/- mouse model with propranolol, a ß-adrenergic antagonist, and epigallocatechin gallate (EGCG), an antioxidant from green tea extract, both of which displaying additional anti-inflammatory properties. In vivo motor and cognitive behavioral tests and ex vivo histopathological brain analyses were used as parameters to assess the therapeutic potential of propranolol and EGCG. After 2 months of treatment, we observed an improvement not only in attention defects but also in neuronal disorganization, astrogliosis, and microgliosis present in the hippocampus of Epm2b-/- mice. In general, propranolol intervention was more effective than EGCG in preventing the appearance of astrocyte and microglia reactivity. In summary, our results confirm the potential therapeutic effectiveness of the modulators of inflammation as novel treatments in Lafora disease.
Subject(s)
Brain/pathology , Inflammation/pathology , Lafora Disease/pathology , Animals , Biomarkers/metabolism , Brain/drug effects , Brain/physiopathology , Catechin/analogs & derivatives , Catechin/pharmacology , Disease Models, Animal , Gliosis/complications , Gliosis/pathology , Gliosis/physiopathology , Glucans/pharmacology , Hippocampus/drug effects , Hippocampus/metabolism , Hippocampus/pathology , Hippocampus/physiopathology , Inclusion Bodies/drug effects , Inclusion Bodies/metabolism , Inflammation/complications , Inflammation/physiopathology , Lafora Disease/complications , Lafora Disease/physiopathology , Mice, Inbred C57BL , Mice, Knockout , Microglia/drug effects , Microglia/metabolism , Microglia/pathology , Motor Activity , Nerve Degeneration/complications , Nerve Degeneration/pathology , Nerve Degeneration/physiopathology , Neurons/drug effects , Neurons/pathology , Phenotype , Propranolol/pharmacology , Ubiquitin-Protein Ligases/deficiency , Ubiquitin-Protein Ligases/metabolismSubject(s)
Lafora Disease/genetics , Adolescent , Anticonvulsants/therapeutic use , Disease Progression , Drug Resistant Epilepsy/genetics , Drug Resistant Epilepsy/physiopathology , Electroencephalography , Epilepsy, Generalized/etiology , Female , Humans , Lafora Disease/drug therapy , Lafora Disease/physiopathology , Protein Tyrosine Phosphatases, Non-Receptor/geneticsABSTRACT
PURPOSE: To elucidate the presenting symptoms of Lafora Disease (LD) to differentiate it from Juvenile Myoclonic Epilepsy (JME). METHODS: We collected and evaluated the early electroclinical data of 5 unrelated Apulian (Southern Italy) LD families, 30 LD patients selected from the literature, and 30 Apulian JME patients. RESULTS: The Apulian LD patients presented with generalised tonic-clonic and focal visual seizures, followed by myoclonic seizures and action-postural myoclonus. In these patients, EEG background slowing and occipital epileptiform abnormalities were significantly more evident than in the other groups. Genetic analysis revealed the presence of mutations in the EPM2A gene in 4 families, and in the NHLRC1 gene in the remaining family. In detail, we identified 2 different point mutations in EPM2A and only 1 in NHLRC1, and expanded the molecular spectrum of the EPM2A gene mutations reporting for the first time a patient carrier of the c.243_246del genetic variant. In the previously reported LD cases, generalised tonic-clonic and focal visual seizures and myoclonus were the most frequent symptoms, as confirmed by the first EEGs showing occipital or diffuse epileptiform abnormalities with photosensitivity in the background activity slowing. In the Apulian JME patients, myoclonus appeared earlier, usually at awakening, with diffuse epileptiform abnormalities during sleep and photosensitivity in the normal background activity. The diagnosis of JME was established much earlier than the LD one. During evolution, unlike JME patients, LD patients showed a significant resistance to drugs. CONCLUSIONS: Tonic-clonic and focal visual seizures followed by myoclonic seizures and action-postural myoclonus together with EEG background slowing with diffuse and occipital epileptiform abnormalities suggest a diagnosis of LD. An early molecular confirmation allows a better diagnosis, counselling and management of affected patients and their families, and it may be useful to improve the patients' quality of life using, when possible, emerging personalized treatments that may slow the evolution of the disease.
Subject(s)
Lafora Disease/genetics , Lafora Disease/physiopathology , Mutation/genetics , Myoclonic Epilepsy, Juvenile/genetics , Seizures/genetics , Adolescent , Adult , Carrier Proteins/genetics , Child , Female , Genetic Testing , Humans , Italy , Male , Protein Tyrosine Phosphatases, Non-Receptor/genetics , Quality of Life , Young AdultABSTRACT
Our goal was to assess the interrater agreement (IRA) of photoparoxysmal response (PPR) using the classification proposed by a task force of the International League Against Epilepsy (ILAE), and a simplified classification system proposed by our group. In addition, we evaluated IRA of epileptiform discharges (EDs) and the diagnostic significance of the electroencephalographic (EEG) abnormalities. We used EEG recordings from the European Reference Network (EpiCARE) and Standardized Computer-based Organized Reporting of EEG (SCORE). Six raters independently scored EEG recordings from 30 patients. We calculated the agreement coefficient (AC) for each feature. IRA of PPR using the classification proposed by the ILAE task force was only fair (AC = 0.38). This improved to a moderate agreement by using the simplified classification (AC = 0.56; P = .004). IRA of EDs was almost perfect (AC = 0.98), and IRA of scoring the diagnostic significance was moderate (AC = 0.51). Our results suggest that the simplified classification of the PPR is suitable for implementation in clinical practice.
Subject(s)
Brain/physiopathology , Electroencephalography , Epilepsy/classification , Photosensitivity Disorders/classification , Adolescent , Adult , Child , Child, Preschool , Epilepsies, Myoclonic/physiopathology , Epilepsy/physiopathology , Epilepsy, Absence/physiopathology , Female , Humans , Infant , Lafora Disease/physiopathology , Male , Middle Aged , Mitochondrial Encephalomyopathies/physiopathology , Myoclonic Epilepsy, Juvenile/physiopathology , Neurofibromatosis 1/physiopathology , Neuronal Ceroid-Lipofuscinoses/physiopathology , Observer Variation , Photic Stimulation , Photosensitivity Disorders/physiopathology , Reproducibility of Results , Rett Syndrome/physiopathology , Young AdultABSTRACT
We report the atypical presentation of Lafora disease in a Senegalese girl carrying the homozygous variant, c.560A>C, in the NHLRC1 gene. At 13 years, the patient developed myoclonic and visual seizures, progressive psychomotor slowing, and cognitive decline. At 14 years, a neurological examination showed severe hypomimia, bradykinesia, rigidity and low-amplitude myoclonic jerks. Flash-visual and somatosensory evoked potentials showed an increased amplitude of the cortical components, while an electroretinogram showed attenuated responses. An EEG showed diffuse polyspikes associated with positive-negative jerks as well as posterior slow waves and irregular spikes. The electroclinical picture suggested the diagnosis of Lafora disease regarding the association of visual seizures, cognitive deterioration, and action myoclonus, together with the EEG and evoked potential findings. Two uncommon findings were the prominence of extrapyramidal signs in the early stage of disease (which are rarely reported) and attenuation of electroretinal responses. We consider that Lafora disease should be included in the diagnostic work-up for juvenile Parkinsonism, when associated with epilepsy.
Subject(s)
Cognitive Dysfunction , Lafora Disease , Parkinsonian Disorders , Adolescent , Cognitive Dysfunction/etiology , Cognitive Dysfunction/physiopathology , Electroencephalography , Evoked Potentials/physiology , Female , Humans , Lafora Disease/complications , Lafora Disease/genetics , Lafora Disease/physiopathology , Parkinsonian Disorders/etiology , Parkinsonian Disorders/physiopathology , Retina/physiopathology , Senegal , Ubiquitin-Protein Ligases/geneticsABSTRACT
Lafora's disease is a neurodegenerative disorder caused by recessive loss-of-function mutations in the EPM2A (laforin glycogen phosphatase) or EPM2B (malin E3 ubiquitin ligase) genes. Neuropathology is characterized by malformed precipitated glycogen aggregates termed Lafora bodies. Asymptomatic until adolescence, patients undergo first insidious then rapid progressive myoclonus epilepsy toward a vegetative state and death within a decade. Laforin and malin interact to regulate glycogen phosphorylation and chain length pattern, the latter critical to glycogen's solubility. Significant gaps remain in precise mechanistic understanding. However, demonstration that partial reduction in brain glycogen synthesis near-completely prevents the disease in its genetic animal models opens a direct present path to therapy.
Subject(s)
Lafora Disease , Animals , Humans , Lafora Disease/genetics , Lafora Disease/metabolism , Lafora Disease/physiopathology , Lafora Disease/therapySubject(s)
Lafora Disease/genetics , Mutation , Parkinsonian Disorders/genetics , Protein Tyrosine Phosphatases, Non-Receptor/genetics , Adolescent , Cognitive Dysfunction/genetics , Cognitive Dysfunction/physiopathology , Drug Resistant Epilepsy/drug therapy , Drug Resistant Epilepsy/genetics , Drug Resistant Epilepsy/physiopathology , Drug Resistant Epilepsy/psychology , Female , Humans , Lafora Disease/drug therapy , Lafora Disease/physiopathology , Lafora Disease/psychology , Parkinsonian Disorders/drug therapy , Parkinsonian Disorders/physiopathology , Parkinsonian Disorders/psychology , PhenotypeSubject(s)
Cardiomyopathies , Dual-Specificity Phosphatases/genetics , Glycogen/metabolism , Lafora Disease , Ubiquitin-Protein Ligases/genetics , Ventricular Dysfunction, Left , Animals , Cardiomyopathies/congenital , Cardiomyopathies/diagnosis , Cardiomyopathies/metabolism , Cardiomyopathies/physiopathology , Disease Models, Animal , Echocardiography/methods , Humans , Lafora Disease/diagnosis , Lafora Disease/genetics , Lafora Disease/physiopathology , Mice , Mice, Knockout , Mutation , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/pathology , Protein Tyrosine Phosphatases, Non-Receptor , Seizures/diagnosis , Seizures/etiology , Stroke Volume , Ventricular Dysfunction, Left/diagnosis , Ventricular Dysfunction, Left/genetics , Ventricular Dysfunction, Left/physiopathology , Ventricular Remodeling/geneticsABSTRACT
Lafora disease (LD), also known as progressive myoclonic epilepsy-2 (EPM2), is a rare, fatal autosomal recessive disorder typically starting during adolescence in otherwise neurologically normal individuals. It is clinically characterized by insidious of progressive neurological features including seizures, action myoclonus, visual hallucination, ataxia and dementia. Mutations in the laforin (EPM2A) gene on chromosome 6q24 or in the malin gene (NHLRC1) on chromosome 6p22 are responsible of LD phenotype. Diagnostic workup includes genetic analysis as well as axillary skin biopsy with evidence of typical periodic acid-Schiff (PAS)-positive polyglucosan inclusion bodies (Lafora bodies) in the apocrine glands and/or in the eccrine duct. Usually, genotype-phenotype correlations do not reveal substantial differences between patients carrying EPM2A and NHLRC1 mutations, but a few specific NHLRC1 mutations appear to correlate with a late onset and slow progressing LD. We report a case of LD due to compound heterozygote NHLRC1 mutation in an adolescent presenting with severe and atypical electro-clinical features, mimicking an autoimmune encephalopathy, and a rapidly progressive clinical course.
Subject(s)
Carrier Proteins/genetics , Lafora Disease/genetics , Lafora Disease/physiopathology , Adolescent , Humans , Lafora Disease/diagnosis , Male , Ubiquitin-Protein LigasesABSTRACT
A 17-year-old female, of consanguineous parents, presented with a history of seizures and cognitive decline since the age of 12 years. She had absence, focal dyscognitive, generalized myoclonic, and generalized tonic-clonic seizures, all of which were drug resistant. The diagnosis of Lafora body disease was made based on a compatible clinical, EEG, seizure semiology picture and a disease-causing homozygous mutation in the EPM2A gene. A vagus nerve stimulator (VNS) was inserted and well tolerated with a steady decrease and then stabilization in seizure frequency during the six months following insertion (months 1-6). At follow-up, at 12 months after VNS insertion, there was a persistent improvement. Seizure frequency during months 7-12, compared to pre-VNS, was documented as follows: the absence seizures observed by the family had decreased from four episodes per month to 0 per month, the focal dyscognitive seizures from 300 episodes per month to 90 per month, the generalized myoclonic seizures from 90 clusters per month to eight per month, and the generalized tonic-clonic seizures from 30 episodes per month to 1.5 per month on average. To our knowledge, this is the second case reported in the literature showing efficacy of VNS in the management of seizures in Lafora body disease.
Subject(s)
Lafora Disease/physiopathology , Lafora Disease/therapy , Vagus Nerve Stimulation/methods , Adolescent , Consanguinity , Female , Humans , Lafora Disease/genetics , Protein Tyrosine Phosphatases, Non-ReceptorABSTRACT
Lafora disease (LD) is progressive myoclonic epilepsy with late childhood- to teenage-onset. Mutations in two genes, EPM2A and NHLRC1, are responsible for this autosomal recessive disease in many patients Worldwide. In present study, we reported two unrelated consanguineous Pakistani families with Lafora disease (Families A and B). Affected individuals in both families presented with generalized tonic clonic seizures, intellectual disability, ataxia and cognitive decline. Diagnosis of Lafora disease was made on histo-pathological analysis of the skin biopsy, found positive for lafora bodies in periodic acid schiff stain and frequent generalized epileptiform discharges on electroencephalogram (EEG). Bi-directional sequencing in family A was performed for EPM2A and NHLRC1 genes but no mutation was found. In family B, Illumina TruSight One Sequencing Panel covering 4813 OMIM genes was carried out and we identified a novel homozygous mutation c.95G>T; p.32Trp>Leu of EPM2A gene which was found co-segregated in this family through Sanger sequencing. Structural analysis of this mutation, through different in silico approaches, predicted loss of stability and conformation in Laforin protein.
Subject(s)
Lafora Disease/diagnosis , Lafora Disease/genetics , Protein Tyrosine Phosphatases, Non-Receptor/genetics , Adolescent , Adult , Brain/diagnostic imaging , Brain/physiopathology , Carrier Proteins/genetics , Diagnosis, Differential , Female , Humans , Lafora Disease/pathology , Lafora Disease/physiopathology , Mutation , Pakistan , Protein Tyrosine Phosphatases, Non-Receptor/metabolism , Skin/pathology , Ubiquitin-Protein LigasesABSTRACT
Lafora disease (LD) is an autosomal recessive progressive myoclonus epilepsy due to mutations in the EPM2A (laforin) and EPM2B (malin) genes, with no substantial genotype-phenotype differences between the two. Founder effects and recurrent mutations are common, and mostly isolated to specific ethnic groups and/or geographical locations. Pathologically, LD is characterized by distinctive polyglucosans, which are formations of abnormal glycogen. Polyglucosans, or Lafora bodies (LB) are typically found in the brain, periportal hepatocytes of the liver, skeletal and cardiac myocytes, and in the eccrine duct and apocrine myoepithelial cells of sweat glands. Mouse models of the disease and other naturally occurring animal models have similar pathology and phenotype. Hypotheses of LB formation remain controversial, with compelling evidence and caveats for each hypothesis. However, it is clear that the laforin and malin functions regulating glycogen structure are key. With the exception of a few missense mutations LD is clinically homogeneous, with onset in adolescence. Symptoms begin with seizures, and neurological decline follows soon after. The disease course is progressive and fatal, with death occurring within 10 years of onset. Antiepileptic drugs are mostly non-effective, with none having a major influence on the progression of cognitive and behavioral symptoms. Diagnosis and genetic counseling are important aspects of LD, and social support is essential in disease management. Future therapeutics for LD will revolve around the pathogenesics of the disease. Currently, efforts at identifying compounds or approaches to reduce brain glycogen synthesis appear to be highly promising.
Subject(s)
Lafora Disease , Animals , Disease Models, Animal , Genetic Counseling , Glycogen/metabolism , Humans , Lafora Disease/drug therapy , Lafora Disease/genetics , Lafora Disease/metabolism , Lafora Disease/physiopathology , Mice , Protein Tyrosine Phosphatases, Non-Receptor/geneticsABSTRACT
Lafora disease (LD, OMIM 254780) is a rare fatal neurodegenerative disorder that usually occurs during childhood with generalized tonic-clonic seizures, myoclonus, absences, drop attacks, or visual seizures. Unfortunately, at present, available treatments are only palliatives and no curative drugs are available yet. The hallmark of the disease is the accumulation of insoluble polyglucosan inclusions, called Lafora bodies (LBs), within the neurons but also in heart, muscle, and liver cells. Mouse models lacking functional EPM2A or EPM2B genes (the two major loci related to the disease) recapitulate the Lafora disease phenotype: they accumulate polyglucosan inclusions, show signs of neurodegeneration, and have a dysregulation of protein clearance and endoplasmic reticulum stress response. In this study, we have subjected a mouse model of LD (Epm2b-/-) to different pharmacological interventions aimed to alleviate protein clearance and endoplasmic reticulum stress. We have used two chemical chaperones, trehalose and 4-phenylbutyric acid. In addition, we have used metformin, an activator of AMP-activated protein kinase (AMPK), as it has a recognized neuroprotective role in other neurodegenerative diseases. Here, we show that treatment with 4-phenylbutyric acid or metformin decreases the accumulation of Lafora bodies and polyubiquitin protein aggregates in the brain of treated animals. 4-Phenylbutyric acid and metformin also diminish neurodegeneration (measured in terms of neuronal loss and reactive gliosis) and ameliorate neuropsychological tests of Epm2b-/- mice. As these compounds have good safety records and are already approved for clinical uses on different neurological pathologies, we think that the translation of our results to the clinical practice could be straightforward.
Subject(s)
Brain/pathology , Lafora Disease/drug therapy , Lafora Disease/pathology , Animals , Disease Models, Animal , Fluorescent Antibody Technique , Gliosis/complications , Gliosis/drug therapy , Gliosis/pathology , Glucans/metabolism , Hippocampus/drug effects , Hippocampus/pathology , Inclusion Bodies/drug effects , Inclusion Bodies/metabolism , Lafora Disease/parasitology , Lafora Disease/physiopathology , Metformin/pharmacology , Metformin/therapeutic use , Mice, Inbred C57BL , Mice, Knockout , Nerve Degeneration/complications , Nerve Degeneration/drug therapy , Nerve Degeneration/pathology , Neuropsychological Tests , Phenylbutyrates/pharmacology , Phenylbutyrates/therapeutic use , Protein Aggregates/drug effects , Trehalose/pharmacology , Trehalose/therapeutic use , Ubiquitin-Protein Ligases/deficiency , Ubiquitin-Protein Ligases/metabolism , Ubiquitinated Proteins/metabolismABSTRACT
Lafora disease (LD; OMIM 254780, ORPHA501) is a devastating neurodegenerative disorder characterized by the presence of glycogen-like intracellular inclusions called Lafora bodies and caused, in most cases, by mutations in either the EPM2A or the EPM2B gene, encoding respectively laforin, a phosphatase with dual specificity that is involved in the dephosphorylation of glycogen, and malin, an E3-ubiquitin ligase involved in the polyubiquitination of proteins related to glycogen metabolism. Thus, it has been reported that laforin and malin form a functional complex that acts as a key regulator of glycogen metabolism and that also plays a crucial role in protein homeostasis (proteostasis). Regarding this last function, it has been shown that cells are more sensitive to ER stress and show defects in proteasome and autophagy activities in the absence of a functional laforin-malin complex. More recently, we have demonstrated that oxidative stress accompanies these proteostasis defects and that various LD models show an increase in reactive oxygen species and oxidative stress products together with a dysregulated antioxidant enzyme expression and activity. In this review we discuss possible connections between the multiple defects in protein homeostasis present in LD and oxidative stress.
Subject(s)
Lafora Disease/etiology , Oxidative Stress , Proteostasis Deficiencies/metabolism , Antioxidants/metabolism , Carrier Proteins/genetics , Glycogen/metabolism , Humans , Lafora Disease/metabolism , Lafora Disease/physiopathology , Mutation , Protein Tyrosine Phosphatases, Non-Receptor/genetics , Ubiquitin-Protein LigasesABSTRACT
We report clinical, neurophysiologic, and genetic features of an Italian series of patients with Lafora disease (LD) to identify distinguishing features of those with a slowly progressive course. Twenty-three patients with LD (17 female; 6 male) were recruited. Mean age (± SD) at the disease onset was 14.5 ± 3.9 years and mean follow-up duration was 13.2 ± 8.0 years. NHLRC1 mutations were detected in 18 patients; EPM2A mutations were identified in 5. Patients who maintained >10 years gait autonomy were labeled as "mild" and were compared with the remaining LD patients with a typical course. Six of 23 patients were mild and presented significantly delay in the age at onset, lower neurologic disability score at 4 years after the onset, less severe seizure phenotype, lower probability of showing both photoparoxysmal response on electroencephalography (EEG) and giant somatosensory evoked potentials, as compared to patients with typical LD. However, in both mild and typical LD patients, EEG showed disorganization of background activity and frequent epileptiform abnormalities. Mild LD patients had NHLRC1 mutations and five of six carried homozygous or compound heterozygous D146N mutation. This mutation was found in none of the patients with typical LD. The occurrence of specific NHLRC1 mutations in patients with mild LD should be taken into account in clinical practice for appropriate management and counseling.
Subject(s)
Carrier Proteins/genetics , Lafora Disease , Mutation , Protein Tyrosine Phosphatases, Non-Receptor/genetics , Adolescent , Adult , Electroencephalography , Female , Humans , Italy , Lafora Disease/genetics , Lafora Disease/physiopathology , Lafora Disease/therapy , Longitudinal Studies , Male , Middle Aged , Ubiquitin-Protein Ligases , Young AdultABSTRACT
OBJECTIVE: To define the clinical spectrum and etiology of progressive myoclonic epilepsies (PMEs) in Italy using a database developed by the Genetics Commission of the Italian League against Epilepsy. METHODS: We collected clinical and laboratory data from patients referred to 25 Italian epilepsy centers regardless of whether a positive causative factor was identified. PMEs of undetermined origins were grouped using 2-step cluster analysis. RESULTS: We collected clinical data from 204 patients, including 77 with a diagnosis of Unverricht-Lundborg disease and 37 with a diagnosis of Lafora body disease; 31 patients had PMEs due to rarer genetic causes, mainly neuronal ceroid lipofuscinoses. Two more patients had celiac disease. Despite extensive investigation, we found no definitive etiology for 57 patients. Cluster analysis indicated that these patients could be grouped into 2 clusters defined by age at disease onset, age at myoclonus onset, previous psychomotor delay, seizure characteristics, photosensitivity, associated signs other than those included in the cardinal definition of PME, and pathologic MRI findings. CONCLUSIONS: Information concerning the distribution of different genetic causes of PMEs may provide a framework for an updated diagnostic workup. Phenotypes of the patients with PME of undetermined cause varied widely. The presence of separate clusters suggests that novel forms of PME are yet to be clinically and genetically characterized.
Subject(s)
Lafora Disease/diagnosis , Lafora Disease/epidemiology , Unverricht-Lundborg Syndrome/diagnosis , Unverricht-Lundborg Syndrome/epidemiology , Adolescent , Adult , Cluster Analysis , Female , Follow-Up Studies , Humans , Italy/epidemiology , Lafora Disease/physiopathology , Male , Middle Aged , Myoclonic Epilepsies, Progressive/diagnosis , Myoclonic Epilepsies, Progressive/epidemiology , Myoclonic Epilepsies, Progressive/physiopathology , Unverricht-Lundborg Syndrome/physiopathology , Young AdultABSTRACT
Lafora disease is a fatal neurodegenerative condition characterized by the accumulation of abnormal glycogen inclusions known as Lafora bodies. It is an autosomal recessive disorder caused by mutations in either the laforin or malin gene. To study whether glycogen is primarily responsible for the neurodegeneration in Lafora disease, we generated malin knockout mice with impaired (totally or partially) glycogen synthesis. These animals did not show the increase in markers of neurodegeneration, the impairments in electrophysiological properties of hippocampal synapses, nor the susceptibility to kainate-induced epilepsy seen in the malin knockout model. Interestingly, the autophagy impairment that has been described in malin knockout animals was also rescued in this double knockout model. Conversely, two other mouse models in which glycogen is over-accumulated in the brain independently of the lack of malin showed impairment in autophagy. Our findings reveal that glycogen accumulation accounts for the neurodegeneration and functional consequences seen in the malin knockout model, as well as the impaired autophagy. These results identify the regulation of glycogen synthesis as a key target for the treatment of Lafora disease.
Subject(s)
Autophagy , Dual-Specificity Phosphatases/metabolism , Glycogen Synthase/genetics , Glycogen/metabolism , Lafora Disease/physiopathology , Ubiquitin-Protein Ligases/genetics , Animals , Biomarkers/metabolism , Disease Models, Animal , Electrical Synapses/metabolism , Epilepsy/chemically induced , Epilepsy/pathology , Glycogen Synthase/metabolism , Hippocampus/physiology , Humans , Inclusion Bodies/genetics , Inclusion Bodies/metabolism , Kainic Acid/pharmacology , Lafora Disease/metabolism , Lafora Disease/pathology , Mice , Mice, Knockout , Mutation , Protein Tyrosine Phosphatases, Non-Receptor , Ubiquitin-Protein Ligases/metabolismABSTRACT
Lafora disease (LD) is a fatal progressive myoclonus epilepsy characterized neuropathologically by aggregates of abnormally structured glycogen and proteins (Lafora bodies [LBs]), and neurodegeneration. Whether LBs could be prevented by inhibiting glycogen synthesis and whether they are pathogenic remain uncertain. We genetically eliminated brain glycogen synthesis in LD mice. This resulted in long-term prevention of LB formation, neurodegeneration, and seizure susceptibility. This study establishes that glycogen synthesis is requisite for LB formation and that LBs are pathogenic. It opens a therapeutic window for potential treatments in LD with known and future small molecule inhibitors of glycogen synthesis.